http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7517792

Outgoing Links

Predicate Object
contentType Journal Article
issn 2666-3643
issueIdentifier 2
pageRange 100009-
publicationName JTO Clinical and Research Reports
startingPage 100009
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b75526fe5b5d33380b7cda018d26f82c
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c1c4b2239c1fe2047bc2eb3481c88a0a
bibliographicCitation Jiang W, Guan R, Shao YW, Wang B, Wang Y. Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib. JTO Clinical and Research Reports. 2020 Jun;1(2):100009. doi: 10.1016/j.jtocrr.2020.100009.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2034de572aea66616378ac01dac3de77
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e065ec6331a195ecfd0ffc15d7569c9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31ebece4d86132105bee8dc34c9dd35d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e48f070c791b5c4107fb125c39baf0e2
date 202006
identifier https://doi.org/10.1016/j.jtocrr.2020.100009
https://pubmed.ncbi.nlm.nih.gov/PMC8474269
https://pubmed.ncbi.nlm.nih.gov/34589922
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/49842
https://portal.issn.org/resource/ISSN/2666-3643
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68165256
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560

Total number of triples: 27.